Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2021-09-14 00:00:00 ET · period of report 2021-09-10 · accession 0001819790-21-000031 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-09-14 | 2021-09-10 | TARS | Mottiwala Aziz | Chief Commercial Off | M - OptEx | $7.05 | +6,943 | 58.2K | +14% | +$49.0K |
| D | 2021-09-14 | 2021-09-10 | TARS | Mottiwala Aziz | Chief Commercial Off | S - Sale+OE | $22.15 | -2,593 | 58.2K | -4% | -$57.4K |
| DM | 2021-09-14 | 2021-09-10 | TARS | Mottiwala Aziz | Chief Commercial Off | M - OptEx | $7.05 | -6,943 | 772 | -90% | -$49.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-10 | M | A | 2,593 | $0.45 | 60,796 | D | — | — | |
| 2 | Common | Common Stock | 2021-09-10 | S | D | 2,593 | $22.15 | 58,203 | D | — | — | (F1) The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $22.000 to $22.200. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2021-09-10 | M | A | 4,350 | $10.99 | 58,203 | D | — | — | |
| 4 | Derivative | Employee Stock Option (right to buy) | 2021-09-10 | M | D | 4,350 | $10.99 | 14,989 | D | $10.99 · — to 2030-09-24 | 4,350 Common Stock | (F2) Option granted under the Tarsus Pharmaceuticals, Inc. 2016 Stock Plan (the "Plan"). The option shares vest and become exercisable in 48 equal monthly installments beginning on October 25, 2020. |
| 5 | Derivative | Employee Stock Option (right to buy) | 2021-09-10 | M | D | 2,593 | $0.45 | 772 | D | $0.45 · — to 2028-09-13 | 2,593 Common Stock | (F3) Option granted under the Plan. 25% of the option shares vested and became exercisable on July 27, 2019 and the remaining option shares vest and become exercisable in 36 equal monthly installments thereafter. |